Other
Estimated Fair Value
Gilead Sciences Estimated Fair Value decreased by 67.2% to $997.00M in Q1 2026 compared to the prior quarter. Over 4 years (FY 2020 to FY 2025), Estimated Fair Value shows an upward trend with a 10.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryLiquidity
SignalHigher is better
VolatilityVolatile
First reportedQ4 2020
Last reportedQ1 2026May 7, 2026
How to read this metric
An increase relative to amortized cost indicates unrealized gains, while a decrease indicates unrealized losses due to market volatility or interest rate changes.
Detailed definition
The current market value of debt securities classified as available-for-sale, excluding accrued interest. This metric pr...
Peer comparison
Standard for insurers; peers with similar duration profiles will show similar sensitivity to market interest rate changes.
Metric ID:
other_debt_securities_available_for_sale_excluding_accru_fbe99dHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.52B | $2.49B | $2.50B | $2.51B | $2.29B | $2.29B | $2.29B | $2.33B | $2.34B | $2.38B | $2.43B | $1.99B | $2.02B | $3.04B | $997.00M |
| QoQ Change | — | -1.3% | +0.3% | +0.7% | -8.9% | +0.0% | +0.1% | +1.4% | +0.6% | +1.8% | +1.8% | -17.9% | +1.6% | +50.4% | -67.2% |
| YoY Change | — | — | — | — | -9.2% | -8.0% | -8.2% | -7.5% | +2.2% | +4.0% | +5.8% | — | — | — | — |
Range$997.00M – $3.04B
CAGR-23.3%
Avg YoY Growth-3.0%
Median YoY Growth-7.5%
Estimated Fair Value at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's estimated fair value?
- Gilead Sciences (GILD) reported estimated fair value of $997.00M in Q1 2026.
- What is the long-term trend for Gilead Sciences's estimated fair value?
- Over 4 years (2020 to 2025), Gilead Sciences's estimated fair value has grown at a 10.7% compound annual growth rate (CAGR), from $2.03B to $3.04B.
- What does estimated fair value mean?
- The current market price of the company's available-for-sale debt investments.